Market reactionShares rose 11% on Nov 4.
NRx Pharmaceuticals is a clinical-stage company developing preservative-free IV ketamine (NRX-100) for suicidal depression and NRX-101 for bipolar depression; neither is approved for these uses.
NRx's near-term opportunity is preservative-free ketamine ANDA approval and launch, with a November 10, 2026 goal date. Completed manufacturing validation strengthens launch readiness; minor labeling changes remain requested. Separately, the NRX-100 suicidal-depression NDA relies on real-world evidence from more than 65,000 patients. NRX-101 with robotic TMS adds a DARPA-funded opportunity. The $22.3 million raise strengthened finances, but August guidance for at least one year of operations depends on cash, clinic revenue growth and potential equity issuance.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: FDA approves the preservative-free ketamine ANDA
Will FDA approve the preservative-free ketamine ANDA after NRx addresses labeling requests?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Ketamine manufacturing validation strengthens launch readiness ahead of November 10 ANDA goal
NRx carries two CNS NDAs toward FDA decisions, with NRX-101's Breakthrough-designated bipolar depression filing as the first binary test of the platform's approvability
NRX-100's FDA NDA filing for TRD with suicidality tests whether a preservative-free ketamine formulation can win approval against a crowded NMDA-antagonist field
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Neurology and pain, Psychiatric disorders
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
12 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.